immukin international unit solution for injection
boehringer ingelheim limited - interferon gamma - solution for injection - international unit - interferons
suboxone 2 mg0.5 mg sublingual tablets
zuellig pharma pte. ltd. - buprenorphine hcl; naloxone hcl - tablet, orally disintegrating - 2.16mg - buprenorphine hcl 2.16mg; naloxone hcl 0.61mg
suboxone 8 mg2 mg sublingual tablets
zuellig pharma pte. ltd. - buprenorphine hcl; naloxone hcl - tablet, orally disintegrating - 8.64mg - buprenorphine hcl 8.64mg; naloxone hcl 2.44mg
xeloda tablets 150 mg
dksh singapore pte. ltd. - capecitabine - tablet, film coated - 150 mg - capecitabine 150 mg
xeloda tablets 500 mg
dksh singapore pte. ltd. - capecitabine - tablet, film coated - 500 mg - capecitabine 500 mg
dostinex 500 microgram tablets
pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - cabergoline - tablet - cabergoline 0.5500 µg - other gynecologicals
immukin 2 x 106 iu (0.1mg) solution for injection
boehringer ingelheim limited ellesfield avenue, bracknell, berkshire, rg12 8ys, united kingdom - interferon gamma - solution for injection - interferon gamma 2000000 iu - immunostimulants
fentanyl- fentanyl patch
st. marys medical park pharmacy - fentanyl (unii: uf599785jz) (fentanyl - unii:uf599785jz) - fentanyl 25 ug in 1 h - indications and usage fentanyl transdermal system is indicated for management of persistent, moderate to severe chronic pain that: - requires continuous, around-the-clock opioid administration for an extended period of time, and - cannot be managed by other means such as non-steroidal analgesics, opioid combination products, or immediate-release opioids fentanyl transdermal system should only be used in patients who are already receiving opioid therapy, who have demonstrated opioid tolerance, and who require a total daily dose at least equivalent to fentanyl transdermal system 25 mcg/hr (see dosage and administration). patients who are considered opioid-tolerant are those who have been taking, for a week or longer, at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily, or an equianalgesic dose of another opioid. because serious or life-threatening hypoventilation could result, fentanyl transdermal system is contraindicated for
rebif- interferon beta-1a kit rebif rebidose- interferon beta-1a kit rebif- interferon beta-1a injection, solution rebif- in
emd serono, inc. - interferon beta-1a (unii: xro4566q4r) (interferon beta-1a - unii:xro4566q4r) - interferon beta-1a 8.8 ug in 0.2 ml - rebif is indicated for the treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. rebif is contraindicated in patients with a history of hypersensitivity to natural or recombinant interferon beta, human albumin, or any other component of the formulation. risk summary data from a large population-based cohort study, as well as other published studies over several decades, have not identified a drug-associated risk of major birth defects with the use of interferon beta during early pregnancy. findings regarding a potential risk for low birth weight or miscarriage with the use of interferon beta in pregnancy have been inconsistent (see data) . it is unclear whether, as a class of products, administration of interferon beta therapies to pregnant animals at doses greater than those used clinically results in an increased rate of abortion. the potential for rebif to have adverse effects on em
tretinoin cream
rebel distributors corp - tretinoin (unii: 5688utc01r) (tretinoin - unii:5688utc01r) - tretinoin 0.1 mg in 1 g - tretinoin gel and cream are indicated for topical application in the treatment of acne vulgaris. the safety and efficacy of the long-term use of this product in the treatment of other disorders have not been established. use of the product should be discontinued if hypersensitivity to any of the ingredients is noted.